The integration helps researchers understand disease biology and uncover biomarkers for developing new medicines.
Initial pilot programmes will be available to select pharmaceutical and biotechnology partners. Credit: Gorodenkoff / Shutterstock.com.
QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.
The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
